Alnylam Pharmaceuticals - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Alnylam Pharmaceuticals
ALNY
|
NASDAQ
|
United States
535
+37
Rank
$31.75B
Market Cap
$2.24B
+$ 0.42B
+23.08%
Revenue
$-0.24B
+$ 0.09B
-27.27%
Earnings
2.2K
+0.1K
+6.19%
Employees
About
Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth
08.10.2026 -
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth
08.10.2026 -
3 Great Healthcare Stocks To Own In October 2026
02.10.2026 -
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
29.09.2026 -
Alnylam Needs Stronger Amvuttra Execution To Justify More Upside
26.09.2026